Tempest Therapeutics Inc. stocks have been trading up by 41.62 percent following highly positive oncology pipeline advancement news.
Click Here for a Millionaire's POV on Trading TPST
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Tempest Therapeutics entered an exclusive option deal with Hebei Senlang for a CD7-targeted lentiviral in vivo CAR-T platform and a BCMA/GPRC5D dual-targeting CAR-T now in Phase 1 for multiple myeloma.
- The company also raised about $2.5M through a warrant-based private placement, with TPST shares jumping roughly 35% after-hours on the announcement.
- The Senlang platform would complement Tempest’s existing CD7-targeted LNP in vivo CAR-T work and broaden its “immune reset” pipeline in blood cancers and autoimmune disease.
- Management plans to present TPST’s in vivo CAR-T platform and lead candidate TPST-4003 at the H.C. Wainwright 28th Annual Global Investment Conference, a near-term catalyst for traders.
Live Update At 08:32:50 EDT: On Wednesday, September 16, 2026 Tempest Therapeutics Inc. stock [NASDAQ: TPST] is trending up by 41.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TPST is still a classic early-stage biotech story: heavy on science, light on revenue, and burning cash. The latest quarterly numbers show Tempest Therapeutics posting a net loss of about $5.24M, or roughly $0.34 per share. For traders, that confirms TPST is a development-stage name that lives and dies on data, deals, and financings, not on current profits.
Operating cash flow was about -$2.78M, with free cash flow matching that figure. Tempest ended the period with just over $1.22M in cash, before the new $2.5M warrant-based private placement. That fresh capital matters. It extends TPST’s runway but does not erase the pressure to keep raising money.
The balance sheet is tight. Working capital is negative by roughly $2.75M, and current ratios show limited cushion. TPST also carries long-term debt above $6.27M and has negative equity, which is common but still risky in micro-cap biotech trading.
More Breaking News
- Nebius Group NBIS Surges After Palantir AI Deal
- GNRC Soars As Amazon Data Center Deal Rewrites The Story
- Hecla Mining (HL) Stock Holds Ground As Street Recalibrates Targets
- WULF Stock Rallies As AI Power Deals Transform Outlook
On the chart, TPST has slid from the $1.10–$1.20 area down toward the mid-$0.70s over recent sessions, signaling clear selling pressure before the latest news pop. For active traders, that backdrop sets the stage for sharp squeezes whenever a real catalyst hits.
Why Traders Are Watching TPST Now
Traders suddenly have a reason to care about TPST again. Tempest Therapeutics just locked in an exclusive option with Hebei Senlang Biotechnology for a CD7-targeted lentiviral in vivo CAR-T platform and a portfolio of candidates. The headliner is a BCMA/GPRC5D dual-targeting CAR-T program already in Phase 1 dose escalation for relapsed or refractory multiple myeloma and other hematologic and autoimmune indications.
That matters because most tiny biotechs TPST’s size are stuck in preclinical or very early human data. Here, TPST gains an option on a clinical-stage in vivo CAR-T asset with real patients already being dosed. In the hype-driven world of CAR-T trading, that kind of platform news can reset sentiment fast.
The Street’s first read was clear: when Tempest announced the Senlang option plus a roughly $2.5M private placement via warrants, TPST ripped about 35% after-hours. That type of vertical move tells you shorts were leaning on the name, liquidity was thin, and any positive surprise was going to trigger a scramble.
Strategically, the Senlang platform is not a one-off. Tempest Therapeutics already has its own CD7-targeted LNP in vivo CAR-T platform. Adding a lentiviral in vivo CAR-T angle from Senlang gives TPST multiple shots on goal for its “immune reset” vision across blood cancers and autoimmune disease. That diversification is what momentum biotech traders want: more programs, more possible catalysts, and more reasons for headlines.
On top of that, TPST will present at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting its in vivo CAR-T work and lead candidate TPST-4003. Conferences like this often bring slide decks, pipeline timelines, and sometimes fresh nuggets that spark another trading wave. For now, TPST sits squarely back on watchlists.
Conclusion
Tempest Therapeutics is not a steady compounder; it is a pure catalyst-driven trading vehicle. TPST’s financials show a company burning around a few million dollars per quarter, with negative equity and a small cash pile. The recent $2.5M financing buys time, but it does not change the playbook. TPST must keep delivering news — on Senlang’s in vivo CAR-T platform, on TPST-4003, and on its broader “immune reset” pipeline.
From a trading standpoint, the combination of a beaten-down daily chart, thin float, and a surprise 35% after-hours spike is exactly the mix that momentum traders love to stalk. TPST has already shown it can move. The next question is whether follow-through volume shows up on the regular session and whether news out of the H.C. Wainwright conference adds fuel.
The key for traders is discipline. Know your levels, plan your entries and exits, and never fall in love with a story stock like TPST. As Tim Sykes always reminds his students, “The market doesn’t care about your opinion — it only cares about price and volume. Respect that, cut losses quickly, and you’ll still be around for the next play.” That discipline ties directly into process: As Tim Bohen, lead trainer with StocksToTrade says, “A consistent trading routine beats sporadic action every time. Show up daily, and you’ll start to see the patterns others miss.” For TPST, this latest in vivo CAR-T deal just turned it back into one of those potential plays — strictly for those who understand the risk.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.